Research compound

Retatrutide 10mg

Price

249,00 CHF

Retatrutide 10 mg research-grade lyophilized peptide powder in a glass vial. Retatrutide (LY3437943), marketed here as Reta-Solution, is an investigational multi-receptor peptide agonist that targets the receptors for GIP, GLP-1 and glucagon, and is used in experimental models of obesity, glycemic control and metabolic regulation.

✓Third party tested

✓High purity and quality

✓Research use only

Research use only: this product is intended exclusively for laboratory, analytical or collector purposes. It is not intended for human or veterinary use, food use, dietary supplementation, cosmetic use or as a medicine.

Research Use Only: All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.

Purity

99%+ (HPLC, third-party tested)

Form

Lyophilized peptide powder

Content

10 mg Retatrutide per vial

Packaging

Glass vial with sterile closure

Storage

Store lyophilized at 2–8 °C (desiccated, protect from light)

Molecular formula

C₂₂₁ H₃₄₂ N₄₆ O₆₈

Molecular weight

~4731.4 g·mol⁻¹

Sequence

Multidomain incretin/glucagon analog (GIP/GLP-1/glucagon triple agonist) peptide backbone with C20 fatty diacid and γGlu–(AEEA)₂ side chain for extended PK (Retatrutide, LY3437943).

CAS number

2381089-83-2

In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC). For a compatible research-only solvent, see Bacteriostatic water - 10 ml.

Research Overview

Retatrutide is a next-generation multi-agonist peptide that engages GIP, GLP-1 and glucagon receptors simultaneously. It is used in laboratory and preclinical models to study integrated control of body weight, glucose homeostasis and whole-body energy balance, without implying any therapeutic or clinical use.

Primary Research Areas

Triple GIP/GLP-1/glucagon receptor agonism: Mechanistic studies dissecting receptor pharmacology, biased signaling and downstream pathways triggered by combined incretin and glucagon receptor activation.
Obesity & body-weight regulation models: In vivo models exploring changes in body weight, adiposity, food intake and energy expenditure under Retatrutide-driven multi-agonist signaling.
Glycemic control & metabolic health: Research focused on glucose tolerance, insulin dynamics, hepatic glucose output and broader metabolic homeostasis in preclinical systems.